JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:507-514, doi:10.1016/j.jacc.2005.09.040 (Published online 13 January 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valgimigli, M.
Right arrow Articles by Serruys, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valgimigli, M.
Right arrow Articles by Serruys, P. W.

Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease

A Combined RESEARCH and T-SEARCH Long-Term Analysis

Marco Valgimigli, MD, Patrizia Malagutti, MD, Jiro Aoki, MD, Héctor M. Garcia-Garcia, MD, Gaston A. Rodriguez Granillo, MD, Carlos A.G. van Mieghem, MD, Jurgen M. Ligthart, BSc, Andrew T.L. Ong, MBBS, FRACP, George Sianos, MD, PhD, Evelyn Regar, MD, PhD, Ron T. Van Domburg, PhD, Pim De Feyter, MD, PhD, Peter de Jaegere, MD, PhD and Patrick W. Serruys, MD, PhD*

Erasmus Medical Center, Thoraxcenter, Rotterdam, the Netherlands.


Figure 1
View larger version (13K):

[in a new window]
  		Figure 1 Adverse events in patients treated with sirolimus-eluting stent (SES group) and in patients treated exclusively with paclitaxel-eluting stent implantation (PES group). (A) Cumulative risk of major adverse events (MACE); (B) death or myocardial infarction (MI); and (C) target vessel revascularization (TVR). CI = confidence interval.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.